GSP Crop Science IPO to Open on March 16; Check Price Band, Lot Size, and More
Agrochemical company GSP Crop Science is gearing up for a public debut with a ?400 crore initial public offering (IPO). The company filed its red herring prospectus with SEBI on March 10, 2026
The GSP Crop Science IPO will remain open for subscription from March 16, 2026, to March 18, 2026.
IPO Details
- Issue Structure: The IPO is a book-building issue of ?400 crore, comprising a fresh issue of ?250 crore and an offer for sale of ?160 crore.?
- Price Band: ?304 to ?320 per share
- Lot Size: 46?
- Minimum Investment: ?14,720 per lot for retail investors (at the cut-off price or upper price band)
- Allotment & Listing: The basis of allotment will be finalised by March 20, 2026, and the tentative listing on BSE and NSE is scheduled for March 23, 2026.?
- Book-running Lead Managers: Equirus Capital Private Limited and Motilal Oswal Investment Advisors Limited are the book-running lead managers for the IPO.?
- Registrar: MUFG Intime India Private Limited
- Use of Proceeds: The net proceeds from the fresh issue will be used towards?
- General corporate purposes?
- Repay/prepay outstanding borrowings??
About the Company?
GSP Crop Science is a research-driven agrochemical company with over 40 years of experience in the industry. The company specialises in the development and manufacturing of insecticides, herbicides, fungicides and plant growth regulators in India.?
As of September 30, 2025, the company has secured 524 product registrations across formulations and technical portfolio, granted 102 patents to date and has 108 additional patent applications under review.?
GSP’s revenue from operations declined by 4.25%, from ?1,203.31 crore in Fiscal 2023 to ?1,152.16 crore in Fiscal 2024. Subsequently, revenue from operations grew by 11.74%, increasing from ?1,152.16 crore in fiscal 2024 to ?1,287.39 crore in fiscal 2025.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.